Dr. Jennifer Brooks<\/a><\/strong>, Executive Director at CanPath.<\/p>\n*Cisgendered women and other adults assigned female at birth, such as transgender men and nonbinary people.<\/p>\n
About CanPath<\/h2>\n
The Canadian Partnership for Tomorrow\u2019s Health (CanPath) is Canada\u2019s largest population health cohort and a national platform for health research. Comprised of more than 330,000 volunteer participants across seven regional cohorts, including Atlantic PATH, CanPath is a unique platform that allows scientists to explore how genetics, environment, lifestyle, and behaviour interact and contribute to the development of chronic disease and cancer.<\/p>\n
<\/p>\n
![\"Jennifer](\"https:\/\/canpath.ca\/wp-content\/uploads\/2024\/12\/Jen-Vicki-and-Mark-824x618.jpg\")
<\/p>\n","protected":false},"excerpt":{"rendered":"
Breast cancer is one of the most common cancers and the second leading cause of cancer-related death among women* in Canada, with one in eight women expected to be diagnosed in their lifetime. Early detection through screening can make treatment easier and improve survival rates. In April 2024, the\u00a0US recommended starting breast cancer screening for women in their forties. However,\u00a0Canada\u2019s guidelines, updated in May 2024, did not fully adopt this change, highlighting the need for more research. To address these evidence gaps, the Honourable Mark Holland, Minister of Health for the Government of Canada, announced\u00a0$295,000\u00a0in funding for CanPath to advance research for breast cancer screening. Minister Holland announced this funding at an in-person event at the\u00a0Canadian Cancer Society, which also received funding for breast cancer public awareness. \u201cWhen we think of breast cancer screening, data gaps, and the solutions research can deploy, it\u2019s exceptionally important,\u201d said the\u00a0Honourable Mark Holland, Minister of Health, \u201cso the partnership between the federal government and CanPath is very exciting.\u201d CanPath will use existing Canadian cohort and administrative data to address\u00a0three main objectives: Study differences in screening participation, treatments, and outcomes by race and ethnicity; Understand breast cancer risk factors and how they vary by race and ethnicity; and Analyze screening results, such as recall and biopsy rates, by race and ethnicity. This research aims to create better screening guidelines that consider the diverse needs of all Canadian women. \u201cAnytime we can announce good news and talk about how we can advance research together is an exciting day. It\u2019s so great to get to celebrate these wins together,\u201d says\u00a0Dr. Jennifer Brooks, Executive Director at CanPath. *Cisgendered women and other adults assigned female at birth, such as transgender men and nonbinary people. About CanPath The Canadian Partnership for Tomorrow\u2019s Health (CanPath) is Canada\u2019s largest population health cohort and a national platform for health research. Comprised of more than 330,000 volunteer participants across seven regional cohorts, including Atlantic PATH, CanPath is a unique platform that allows scientists to explore how genetics, environment, lifestyle, and behaviour interact and contribute to the development of chronic disease and cancer. <\/p>\n","protected":false},"author":1,"featured_media":3880,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_eb_attr":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":"","_wpscppro_dont_share_socialmedia":null,"_wpscppro_custom_social_share_image":0,"_facebook_share_type":"default","_twitter_share_type":"default","_linkedin_share_type":"default","_pinterest_share_type":"default","_linkedin_share_type_page":"","_instagram_share_type":"default","_medium_share_type":"","_threads_share_type":"","_selected_social_profile":[],"_wpsp_enable_custom_social_template":false,"_wpsp_social_scheduling":{"enabled":false,"datetime":null,"platforms":[],"status":"template_only","dateOption":"today","timeOption":"now","customDays":"","customHours":"","customDate":"","customTime":"","schedulingType":"absolute"},"_wpsp_active_default_template":true},"categories":[3],"tags":[136,11,36,42,176],"class_list":["post-3878","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-breast-cancer","tag-canpath","tag-cohort","tag-research","tag-screening"],"acf":[],"modified_by":"pathwp","_links":{"self":[{"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/posts\/3878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/comments?post=3878"}],"version-history":[{"count":2,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/posts\/3878\/revisions"}],"predecessor-version":[{"id":3881,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/posts\/3878\/revisions\/3881"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/media\/3880"}],"wp:attachment":[{"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/media?parent=3878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/categories?post=3878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.atlanticpath.ca\/index.php\/wp-json\/wp\/v2\/tags?post=3878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}